Exelixis (EXEL) Set to Announce Earnings on Tuesday

Exelixis (NASDAQ:EXEL) will be announcing its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of $0.35 per share for the quarter. Exelixis has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.44. Exelixis had a return on equity of 15.54% and a net margin of 17.38%. The business had revenue of $637.18 million during the quarter, compared to the consensus estimate of $468.21 million. On average, analysts expect Exelixis to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Exelixis Trading Down 0.8 %

NASDAQ:EXEL opened at $28.66 on Tuesday. Exelixis has a twelve month low of $18.64 and a twelve month high of $29.75. The company has a market cap of $8.69 billion, a price-to-earnings ratio of 44.78, a price-to-earnings-growth ratio of 0.54 and a beta of 0.54. The stock has a fifty day simple moving average of $26.42 and a 200-day simple moving average of $23.83.

Insiders Place Their Bets

In other news, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the transaction, the executive vice president now owns 520,990 shares in the company, valued at $13,024,750. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Dana Aftab sold 95,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the transaction, the executive vice president now owns 520,990 shares in the company, valued at $13,024,750. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now owns 721,680 shares in the company, valued at approximately $19,622,479.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 327,858 shares of company stock worth $8,640,129. 2.85% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

EXEL has been the subject of several research analyst reports. Oppenheimer reiterated an “outperform” rating and set a $29.00 target price on shares of Exelixis in a research report on Tuesday, July 30th. Truist Financial restated a “buy” rating and issued a $33.00 price objective (up from $32.00) on shares of Exelixis in a report on Thursday, August 8th. UBS Group started coverage on Exelixis in a report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective for the company. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a report on Tuesday, October 15th. Finally, Stifel Nicolaus lifted their price objective on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.57.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.